Soleno Therapeutics Inc

6XC

Company Profile

  • Business description

    Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

  • Contact

    100 Marine Parkway
    Suite 400
    Redwood CityCA94065
    USA

    T: +1 650 213-8444

    E: [email protected]

    https://www.soleno.life

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    152

Stocks News & Analysis

stocks

ASX listed software provider joins global sell-off

Our thesis remains unchanged.
stocks

AMD earnings: Data center demand still looks quite strong to us

AMD has the components to target $100 billion of AI revenue in the next few years.
stocks

PayPal earnings: Growth slows, new CEO appointed

We expect to lower our fair value estimate of PayPal stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,154.9049.70-0.54%
CAC 408,275.7713.610.16%
DAX 4024,530.1972.85-0.30%
Dow JONES (US)49,278.3237.330.08%
FTSE 10010,363.9238.42-0.37%
HKSE26,885.2437.920.14%
NASDAQ22,904.58350.61-1.51%
Nikkei 22553,818.04475.32-0.88%
NZX 50 Index13,444.0223.27-0.17%
S&P 5006,848.6269.19-1.00%
S&P/ASX 2008,889.2038.60-0.43%
SSE Composite Index4,075.9226.29-0.64%

Market Movers